Utrecht Holdings supports the founding of spin-off companies. In this video we interview the founders of two of these spin-offs: OctoVascular and Jama Therapeutics.

About OctoVascular

OctoVascular aims to transform coronary artery bypass surgery through minimally invasive innovation. Built on years of clinical and engineering expertise, the company is developing a novel automated vessel connection technology designed to simplify one of the most complex steps in cardiac surgery.

Its primary solution, the Octocon connector, enables surgeons to perform precise vascular connections more efficiently, supporting a shift from traditional open-heart procedures toward endoscopic, beating-heart techniques that reduce trauma and improve surgical consistency.

About Jama Therapeutics

Jama Therapeutics (JAMA Tx) is a biotechnology startup that aims to solve one of the most critical challenges in modern medicine: the safe and effective delivery of genetic therapies. As a spinout from the UMC Utrecht Department of Experimental Cardiology, the company builds on more than two decades of research in extracellular vesicle biology and cardiovascular gene therapy.

Its core mission is to enable precise delivery of RNA, proteins, and programmable gene-editing tools to the heart and other hard-to-reach tissues—areas where current delivery technologies remain limited.